[3H]-18-Vinylprogesterone | 115940-37-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [3H]-18-Vinylprogesterone
• 英文别名: 18-Vinylprogesterone；(8S,9S,10R,13R,14S,17S)-17-acetyl-10-methyl-13-prop-2-enyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 115940-37-9
• 化学式: C₂₃H₃₂O₂
• 分子量: 340.506
• InChiKey: TZDPJVSOAZDLGP-NURQPWONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3β-acetoxy-18-cyano-pregn-5-ene-20-one 在 4-二甲氨基吡啶 、 正丁基锂 、 1-甲基-2-哌啶酮 、 IRN-77 Amberlite 、 四丁基氟化铵 、 aluminum isopropoxide 、 二异丁基氢化铝 、 potassium carbonate 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 124.5h， 生成 [3H]-18-Vinylprogesterone
  参考文献：
  名称：

  Synthesis of new inhibitors of aldosterone biosynthesis

  摘要：

  DOI：

  10.1016/s0040-4020(01)85892-0

文献信息

• Aldosterone blocker therapy to prevent or treat inflammation-related disorders
  申请人：Pharmacia Corporation

  公开号：US20040037806A1

  公开（公告）日：2004-02-26

  A method of preventing or treating an inflammation-related disorder such as myocarditis, cardiomyopathy, vasculitis, and Behcet's disease in a subject, comprising treating the subject with a therapeutically-effective amount of an aldosterone blocker sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation or cardiac remodeling in the subject.

  一种预防或治疗与炎症相关的疾病，如心肌炎、心肌病、血管炎和Behcet病的方法，包括使用治疗剂量的醛固酮受体阻滞剂来治疗受试者，该治疗剂量足以改变与受试者中炎症或心脏重塑调节相关的一个或多个表达产物的表达。
• Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
  申请人：Sapna Life Sciences Corporation

  公开号：US10201569B2

  公开（公告）日：2019-02-12

  Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating injury or trauma to nerve cells, to neural support cells and to neural support tissues.

  本发明提供了用于治疗创伤引起的神经病理学和神经变性的新型多组分制剂、程序和方法。本发明的多组分制剂包括至少一种神经类固醇或神经活性类固醇（如黄体酮或合成孕激素）、至少一种抗癫痫药或抗惊厥药（如加巴喷丁、普瑞巴林或丙戊酸）、至少一种NK-1受体拮抗剂（如阿普瑞坦、卡索匹坦或马替匹坦）、至少一种含锂药物或与锂相关的药物的任意两种、任意三种或全部四种的生物活性形式。所提供的制剂经配置或调整后可预防或降低创伤引起的神经损伤的发生率和严重程度，或降低这种损伤的风险。本发明的制剂、程序和方法既能起到预防或减少二次损伤的神经保护作用，又能起到修复和恢复受创伤影响的细胞和组织的神经营养作用，特别适用于治疗神经细胞、神经支持细胞和神经支持组织的损伤或创伤。
• ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS
  申请人：Pharmacia Corporation

  公开号：EP1368009A2

  公开（公告）日：2003-12-10
• INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY
  申请人：MOR RESEARCH APPLICATIONS LTD.

  公开号：EP1937254A2

  公开（公告）日：2008-07-02
• Inhibition of the Renin-Angiotensin System for the Treatment of Renal, Vascular and Cartilage Pathology
  申请人：Weinstein Talia

  公开号：US20090192119A1

  公开（公告）日：2009-07-30

  A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.